Company Overview and News

7.2% of SCH Group shares traded off-market

2018-10-01 theedgemarkets
KUALA LUMPUR (Oct 1): Some 40 million shares representing a 7.2% stake in quarry equipment company SCH Group Bhd were traded off-market today, according to Bloomberg data.

KLCI set to rise higher, immediate support at 1,750

2018-07-24 theedgemarkets
KUALA LUMPUR (July 25): The FBM KLCI looks set to rise today in line with the firmer overnight close at most global markets, with immediate support seen at 1,750.
4456 4723 7158 MYPRY 9679 5245 5014 0161

Nextgreen, Scomi, Kwantas, SCH, DNEX, WCT, JAKS, AirAsia, MAHB, I-Bhd and Caring Pharmacy

2018-07-24 theedgemarkets
KUALA LUMPUR (July 24): Based on corporate announcements and news flow today, companies that may be in focus on Wednesday (July 25) may include the following: Nextgreen Global Bhd, Scomi Group Bhd, Kwantas Corp Bhd, SCH Group Bhd, Dagang NeXchange Bhd, WCT Holdings Bhd, JAKS Resources Bhd, AirAsia Group Bhd, Malaysia Airports Holdings Bhd, I-Bhd and Caring Pharmacy Group Bhd.
4456 6084 7205 4723 7158 MYPRY 9679 7241 5245 5014 0161

Businessman Koh Kin Lip sells shares in SCH, ceases to be substantial shareholder

2018-07-24 theedgemarkets
KUALA LUMPUR (July 24): Low-profile businessman Tan Sri Richard Koh Kin Lip, Chow Dai Ying and SCH Group Bhd's directors Koh Chen Foong and Liew Fook Meng have ceased to be substantial shareholders of the quarry-based products and machinery group following the disposal of 68 million shares or a 13.19% stake for RM11.56 million or 17 sen per share yesterday.
7205 5151 BSMAF 0161 1818

SCH Group sees 14.4% stake traded off market

2018-07-23 theedgemarkets
KUALA LUMPUR (July 23): SCH Group Bhd saw some 68 million shares, representing a 14.4% stake, traded off market at 17 sen per share.

The Week Ahead: New Cabinet members, PNB chairman and Umno chief

2018-07-02 theedgemarkets
Malaysians will start the week with new members of the Cabinet being sworn in at Istana Negara on Monday (July 2). Before that, Umno will elect a new president over the weekend. Whoever wins the party election will have a big task ahead. He will have to find ways to improve the morale of members and regain the support of voters. The new chief will have to chart a new course for the political party.
8362 7121 0161

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...